SCHEMBL5714769

SCHEMBL5714769

Cc1ccnc(Cc2ccc(OC(=O)N3CCN(c4ccccn4)CC3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 0.53
KDM4E B2RXH2 6/20 0.53
HPGD P15428 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 6/20 0.52
CYP1A2 P05177 3/20 0.52
CYP2C9 P11712 3/20 0.52
CYP2C19 P33261 3/20 0.52
CYP3A4 P08684 3/20 0.52
TSHR P16473 3/20 0.52
MAPK1 P28482 2/20 0.52
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
ALOX15 P16050 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP2D6 P10635 1/20 0.46
SMO Q99835 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714630 0.91 KDM4E (0.52) HSD17B10KDM4EHPGDSMN1; SMN2NPSR1
SCHEMBL5715022 0.89 HSD17B10 (0.58) HSD17B10KDM4EHPGDSMN1; SMN2NPSR1
SCHEMBL5715636 0.89 SMO (0.42) HSD17B10KDM4EHPGDSMN1; SMN2NPSR1
SCHEMBL5714080 0.88 PANK3 (0.48) KDM4EHPGDSMN1; SMN2CYP1A2CYP2C9
SCHEMBL5715171 0.86 KDM4E (0.57) KDM4EALDH1A1TSHRMAPK1MAPT
SCHEMBL5715148 0.86 KDM4E (0.55) HSD17B10KDM4EHPGDSMN1; SMN2NPSR1
SCHEMBL5715211 0.86 PANK3 (0.48) HPGDSMN1; SMN2SMO
SCHEMBL5714885 0.86 PANK3 (0.46) HPGDSMN1; SMN2ALOX15SMO
SCHEMBL5714845 0.85 HRH3 (0.46) HSD17B10KDM4EHPGDSMN1; SMN2NPSR1
SCHEMBL5715642 0.85 PANK3 (0.46) HSD17B10KDM4EHPGDSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HSD17B10 285/4885KDM4E 1353/4885HPGD 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.